Reaction
Discouragement reporting signals
As of the last recalculation, Discouragement appears in 2,283 FAERS reports alongside 44 co-occurring drug terms. The strongest observed disproportionality signal is TOFACITINIB (PRR 61.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Tofacitinib | 808 | 61.3 | 61.5 |
| Ribociclib | 89 | 26.7 | 26.8 |
| Eltrombopag Olamine | 44 | 17.7 | 17.7 |
| Vedolizumab | 136 | 15.2 | 15.3 |
| Thiamine Hydrochloride | 17 | 12.5 | 12.6 |
| Anastrozole Tablets | 27 | 11.6 | 11.6 |
| Fulvestrant | 35 | 9.8 | 9.8 |
| Lanreotide Acetate | 8 | 9.3 | 9.3 |
| Paricalcitol | 14 | 9.1 | 9.1 |
| Acalabrutinib | 11 | 8.3 | 8.3 |
| Venetoclax | 51 | 7.7 | 7.7 |
| Panitumumab | 13 | 7.6 | 7.6 |
| Teduglutide | 11 | 7.5 | 7.5 |
| Letrozole | 46 | 6.9 | 6.9 |
| Anastrozole | 27 | 6.8 | 6.8 |
| Nilotinib | 21 | 6.5 | 6.5 |
| Naltrexone Hydrochloride And Bupropion Hydrochloride | 6 | 6.4 | 6.4 |
| Mesalamine | 39 | 6.4 | 6.4 |
| Rotigotine | 10 | 6.3 | 6.3 |
| Fexofenadine | 11 | 6.1 | 6.1 |
| Erythropoietin | 13 | 5.8 | 5.8 |
| Inclisiran | 5 | 5.7 | 5.7 |
| Hydroxyurea | 13 | 5.6 | 5.6 |
| Dapagliflozin | 19 | 5.5 | 5.5 |
| Losartan | 99 | 5.4 | 5.4 |
| Azacitidine For | 10 | 5.0 | 5.0 |
| Apalutamide | 6 | 4.7 | 4.7 |
| Ruxolitinib | 36 | 4.6 | 4.6 |
| Riociguat | 15 | 4.2 | 4.2 |
| Oral Semaglutide | 31 | 3.9 | 3.9 |
| Azacitidine | 12 | 3.7 | 3.7 |
| Romosozumab-Aqqg | 5 | 3.4 | 3.4 |
| Secukinumab | 56 | 3.2 | 3.2 |
| Abemaciclib | 7 | 3.2 | 3.2 |
| Belimumab | 10 | 2.9 | 2.9 |
| Ixazomib | 9 | 2.9 | 2.9 |
| Brexpiprazole | 5 | 2.7 | 2.8 |
| Abiraterone | 4 | 2.7 | 2.7 |
| Sacubitril And Valsartan | 31 | 2.5 | 2.5 |
| Alirocumab | 6 | 2.2 | 2.2 |
| Olaparib | 5 | 2.2 | 2.2 |
| Enzalutamide | 14 | 2.2 | 2.2 |
| Minoxidil Foam 5% (Womens) | 5 | 1.4 | 1.4 |
| Valbenazine | 3 | 1.1 | 1.1 |